8-K: Syros Pharmaceuticals to Voluntarily Delist from Nasdaq and Deregister with SEC Amid Wind-Down

Syros Pharmaceuticals announces its decision to voluntarily delist from Nasdaq and deregister with the SEC due to financial constraints and the failure of a key clinical trial.

Summary

• Syros Pharmaceuticals has decided to voluntarily delist its common stock from the Nasdaq Global Select Market.
• The company intends to deregister its common stock with the SEC, suspending its reporting obligations.
• This decision follows the failure of the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene, leading to an event of default under its loan agreement with Oxford Finance, LLC.
• Syros will operate under a wind-down plan, limiting expenditures as approved by Oxford.
• The company aims to preserve cash and maximize its cash position for the benefit of its stakeholders.
• The company received deficiency letters from Nasdaq on January 6, 2025, for non-compliance with listing standards, including a share price below $1.00, a Minimum Value of Listed Securities below $50 million, and a Market Value of Publicly Held Shares below $15 million.
• The company will file a Form 25 with the SEC on or about March 10, 2025, with delisting expected around March 20, 2025.
• A Form 15 will be filed on or about March 20, 2025, to suspend reporting obligations, with deregistration expected 90 days after the filing.
• Peter Wirth, Marsha H. Fanucci, and Nancy Simonian, M.D., resigned from the Board, effective immediately on February 28, 2025.
• Gerald Quirk stepped down as CEO and President on March 1, 2025, but will remain on the Board and serve as a consultant.
• Matthew Foster was appointed as Chief Restructuring Officer, effective March 1, 2025.

Sentiment

Score: 2

Explanation: The announcement indicates significant negative developments, including a failed clinical trial, delisting from Nasdaq, and a wind-down of operations. The sentiment is decidedly negative from an investment perspective.

Positives

• The company is taking steps to preserve cash and maximize its cash position for the benefit of its stakeholders during the wind-down process.
• Gerald Quirk will remain on the Board as a director and serve as a consultant to the Company.

Negatives

• The SELECT-MDS-1 Phase 3 trial failure triggered an event of default under the loan agreement with Oxford Finance, LLC.
• The company is non-compliant with Nasdaq listing requirements, including minimum share price and market capitalization.
• The company is incurring significant operating expenses related to Nasdaq reporting requirements.
• The company is undergoing a wind-down of its operations.

Risks

• The company's ability to preserve cash and fund an orderly wind-down is subject to various risks outlined in their SEC filings.
• Actual results could differ materially from forward-looking statements due to important factors described in the company's reports.
• The delisting and deregistration could negatively impact investor confidence and liquidity of the stock.

Future Outlook

The company expects the delisting of its common stock to become effective on or about March 20, 2025, and the deregistration to become effective 90 days after the filing of Form 15 with the SEC. The company aims to preserve cash and maximize its cash position for the benefit of its stakeholders during the wind-down process.

Industry Context

This announcement reflects the challenges faced by biotech companies with unsuccessful clinical trials, leading to financial difficulties and strategic shifts. Delisting and deregistration are often seen as cost-saving measures in such situations.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges when clinical trials fail, often leading to restructuring or acquisition.
• Delisting from major exchanges is a common consequence of non-compliance with listing requirements, particularly related to share price and market capitalization.
• Companies like Geron Corporation and Agenus Inc. have faced similar situations, undergoing restructuring or strategic shifts after clinical trial setbacks.

Management Changes

Stakeholder Impact

• Shareholders will likely experience a decrease in the value of their investment due to the delisting and wind-down.
• Employees may face job losses as the company reduces operations.
• Suppliers and creditors may be impacted by the company's financial difficulties and wind-down.

Next Steps

• File Form 25 with the SEC on or about March 10, 2025.
• Delist common stock from Nasdaq, expected around March 20, 2025.
• File Form 15 with the SEC on or about March 20, 2025.
• Deregister common stock with the SEC, expected 90 days after filing Form 15.

Key Dates